Le Lézard
Classified in: Health, Science and technology
Subject: PDT

Tyber Medical Announces the Full Launch of TyFixtm, An All-in-One Extremity System



BETHLEHEM, Pa., March 8, 2018 /PRNewswire/ -- Tyber Medical, LLC, a privately held company focusing on developing innovative medical devices for private label opportunities and advancing the science of bioengineered surfaces, announces the launch of TyFixtm, an all-in-one extremity joint fixation system.

Tyber Medical announces the full launch of TyFixtm, an all-in-one extremity joint fixation system that integrates implant and instrument design to create value by minimizing the number of procedure steps, improving operating room efficiency, and significantly reducing procedure time.

Tyber Medical is excited to announce the completion of the limited release for the TyFixtm System.  Dr. Michael Gentile, DPM, FACFAS, at Cornell Surgery Center in Beaverton, OR, performed one of the first procedures utilizing the TyFixtm System.  Dr. Gentile commented, "The instrumentation design is efficient and intuitive. A versatile implant with a myriad of sizes and angle options for a reliable fit and natural toe position."

The company received 510(k) clearance in July 2017 for the innovative system that reduces the need for ancillary instrumentation for a wide range of bone fixation procedures.  The TyFixtm System, designed for a variety of procedures, including correction of Hammertoe deformities, allows realignment to relieve pain and discomfort.  The integrated implant/instrument design, first of its kind, creates value by minimizing the number of procedure steps, improving operating room efficiency, and significantly reducing procedure time. In addition, the all-in-one sterile packed device eliminates traditional reprocessing costs.

The TyFixtm screw combines a highly-optimized bone thread with a barbed head to maximize bone purchase and compression in both the proximal and distal phalanges. The system delivers intraoperative flexibility by offering solid and cannulated implants with diameters ranging from Ø1.5 - 4.0mm in multiple lengths as well as a straight and an angled 10o option.

"The TyFixtm System is designed to deliver a construct at the speed of a k-wire and the holding strength of a screw, while also delivering an efficient OR process through the patented fully integrated implant and instrument design." commented Jeff Tyber, CEO of Tyber Medical. He added, "Tyber Medical continues to focus and enhance our distal extremity platform, is dedicated to accelerating the path to market for our private label customers, and is always striving to add value through innovative solutions."

Visit Tyber Medical's Booth #333, at ACFAS in Nashville, TN where the company will showcase the TyFixtm System as well as other innovative products available for private labeling.

About Tyber Medical, LLC.
Tyber Medical, LLC is an orthopedic device manufacturer providing rapid access to portfolio enhancing, regulatory approved, orthopedic implants within the spine and extremity/trauma markets.  While focusing on rapid product commercialization, the company distributes products via private labeling; releasing 14 spine and 25 extremity/trauma systems since its founding in 2012.  Tyber Medical utilizes the differentiated, bioengineered technology such as TyPEEK® osteoconductive coatings and BioTytm, a new antimicrobial nano-textured surface modification to enhance the company's growing portfolio.

Contact:
Eric Dickson 
83 South Commerce Way, Suite 310
Bethlehem PA 18017
(610) 849-1710
edickson@tybermed.com

 

SOURCE Tyber Medical, LLC


These press releases may also interest you

at 00:00
Compare-autoinsurance.org has released a new blog that explains the importance of collision car insurance and why clients should buy it. Collision car insurance is not a mandatory policy and its aim is to reimburse the policyholder for the damage...

22 jun 2018
ModulTrade creates a foundation for the launch of ModulTrade blockchain based smart-contract platform (MT WALLET and MT MARKET) in the African continent after signing agreements with leading financial & logistic organizations and meeting with an...

22 jun 2018
BABB, a UK-based financial venture that uses blockchain technology and biometrics to offer access to banking services for all, is soon to hold an equity crowdsale. The sale will raise money to cover the regulatory and legal costs of obtaining a...

22 jun 2018
Cellenkostm and The University Of Texas Health Science Center at Houston today announce a research collaboration for application of cord blood-derived regulatory T cells (CK0801) as adoptive therapy for treatment of neuroinflammatory disorders. The...

22 jun 2018
In connection with the acquisition by FogChain Corp. ("FogChain" or the "Company") of the RadJav rapid application development platform and other related assets ("RadJav") on June 7, 2018, in a transaction valued at USD$5,000,000 (CAD$6,486,000),...

22 jun 2018
DANVERS, Mass., June 22, 2018 /PRNewswire-PRWeb/ -- Cell Signaling Technology (CST), a leading provider of antibodies, kits, and services announced that two of its antibody clones, ALK (D5F3®) and ROS1 (D4D6®), were featured in an article authored by...




News published on 8 march 2018 at 17:13 and distributed by: